Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 130

Sort by

Sort Order Select

Journal Articles

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Blood (2025) 146 (Supplement 2): LBA-6.

https://doi.org/10.1182/blood-2025-LBA-6

Published: 2025

Journal Articles

Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis

He Li, Jinrong Yang, Yun Tang, Yongqian Jia, Yang Dai, Jie Huang, Bing Xiang, Jie Wang, Xu Sun, Ailin Zhao, Ting Niu

Blood (2025) 146 (Supplement 1): 6303.

https://doi.org/10.1182/blood-2025-6303

Published: 2025

Journal Articles

Multi-dimensional transcriptomic profiling reveals novel tumor microenvironment landscape and subtype-specific therapeutic Vulnerabilities of MALT lymphomas

Yijun Wu, Kai Kang, Xu Sun, Yuqi Yang, Yuhong Liu, Ailin Zhao, Ting Niu

Blood (2025) 146 (Supplement 1): 1751.

https://doi.org/10.1182/blood-2025-1751

Published: 2025

Journal Articles

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

Blood (2025) 146 (Supplement 1): 908.

https://doi.org/10.1182/blood-2025-908

Published: 2025

Journal Articles

A multifunctional nanoplatform for ferroptosis inducing/chemo/photothermal therapy enhances therapeutic effect and prevents adverse gastrointestinal reaction of methotrexate

Mengyao Wang, Qingya Liu, Zhiyong Qian, Ying Qu, He LI, Yi Liao, Yutong Wang, Ting Niu

Blood (2025) 146 (Supplement 1): 6107.

https://doi.org/10.1182/blood-2025-6107

Published: 2025

Journal Articles

Efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia: A retrospective real-world study

Kai Shen, Chenlu Yang, Jinrong Yang, He Li, Jie Wang, Jiazhuo Liu, Yun Tang, Chuan He, Bing Xiang, Ting Niu

Blood (2025) 146 (Supplement 1): 7422.

https://doi.org/10.1182/blood-2025-7422

Published: 2025

Journal Articles

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Blood (2025) 146 (Supplement 1): 5815.

https://doi.org/10.1182/blood-2025-5815

Published: 2025

Journal Articles

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Zi-Xun Yan, Wenbin Qian, Ying Lu, Keshu Zhou, Dongmei Ji, Yuhua Li, Dehui Zou, Lanfang Li, Lei Zhang, Ping Li, Hongmei Jing, Chunyan Ji, Ting Niu, Fei Li, Xiaojian Zhu, Jinghua Zhao, Yu Hu, Depei Wu, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 7230.

https://doi.org/10.1182/blood-2025-7230

Published: 2025

Journal Articles

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

Luqun Wang, Wei Yang, Yafei Wang, Ting Niu, Rong Fu, Yuping Zhong, Wenbin Qian, Kaiyang Ding, Kai Sun, Hong Liu, Baijun Fang, Hui Liu, Yanhui Li, Yishen Yang, Jianmin Zhuo, Xi Chen, Jin Lu

Blood (2025) 146 (Supplement 1): 7529.

https://doi.org/10.1182/blood-2025-7529

Published: 2025

Journal Articles

Research on allogeneic CAR-T.BiTE cells targeting CLL-1/siglec-6 for the treatment of Acute Myeloid Leukemia

Qizhong Lu, Hexian Li, Ting Niu

Blood (2025) 146 (Supplement 1): 7626.

https://doi.org/10.1182/blood-2025-7626

Published: 2025

Journal Articles

Effects of golidocitinib and gecacitinib in mouse models of primary and secondary hemophagocytic lymphohistiocytosis

Yijun Wu, Xu Sun, Kai Kang, He LI, Ailin Zhao, Ting Niu

Blood (2025) 146 (Supplement 1): 1215.

https://doi.org/10.1182/blood-2025-1215

Published: 2025

Journal Articles

A novel conditioning regimen combining selinexor with melphalan Improves Survival in Patients with multiple myeloma:a prospective study

Liangliang Ma, Jingping Zhang, Xiaoqing Chen, Shanglun Yang, Youmei Fei, Qian Hu, Lejia Liu, Rongqiong Liao, Jian Li, Caigang Xu, Ting Niu, Yongqian Jia

Blood (2025) 146 (Supplement 1): 5837.

https://doi.org/10.1182/blood-2025-5837

Published: 2025

Journal Articles

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Blood (2025) 146 (Supplement 1): 88.

https://doi.org/10.1182/blood-2025-88

Published: 2025

Journal Articles

Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis

Kai Shen, Chenlu Yang, Jinrong Yang, He Li, Jie Wang, Jiazhuo Liu, Yun Tang, Chuan He, Bing Xiang, Ting Niu

Blood (2025) 146 (Supplement 1): 7433.

https://doi.org/10.1182/blood-2025-7433

Published: 2025

Journal Articles

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Ting Niu, Lin LIU, Huijing Wu, Keshu Zhou, Wei Yang, Li Wang, Shu Cheng, Jie Wang, Jinrong Yang, Fei Li, Shiyong Zhou, Yanhong Tong, Ke Tan, Adrian Rui Liang, linyu yang, Lijuan Chen, Wei Li Zhao

Blood (2025) 146 (Supplement 1): 5415.

https://doi.org/10.1182/blood-2025-5415

Published: 2025

Journal Articles

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Blood (2025) 146 (Supplement 1): 1796.

https://doi.org/10.1182/blood-2025-1796

Published: 2025

Journal Articles

Early efficacy and safety of luspatercept in myelofibrosis-associated anemia: A clinical study with biomarker exploration

Junyao Huang, Ting Niu, Ling Pan, Huanling Zhu, Yu WU, Yunfan Yang

Blood (2025) 146 (Supplement 1): 1116.

https://doi.org/10.1182/blood-2025-1116

Published: 2025

Journal Articles

DARS mediated M2 polarization of tumor associated macrophages drives MPN progression

Hao xiong, hanlu zhang, Ting Niu, Lijuan li, Liansheng Zhang

Blood (2025) 146 (Supplement 1): 5006.

https://doi.org/10.1182/blood-2025-5006

Published: 2025

Journal Articles

Real-world safety profile of PD-1 inhibitors in Epstein–Barr Virus–Associated lymphoproliferative disorders: A retrospective analysis from west China hospital

Yang Dai, Pengpeng Liu, Yu Wu, Ting Liu, Ting Niu, Manikanta Boda

Blood (2025) 146 (Supplement 1): 3008.

https://doi.org/10.1182/blood-2025-3008

Published: 2025

Journal Articles

S100A12-Orchestrated Macrophage-ER stress crosstalk in MDS: Mechanisms and precision therapeutic targeting

Li Zhang, Liansheng Zhang, Ting Niu, Lijuan li

Blood (2025) 146 (Supplement 1): 6769.

https://doi.org/10.1182/blood-2025-6769

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3

Dual anti-HLH and antitumor efficacy of golidocitinib in relapsed/refractory PTCL-associated hemophagocytic lymphohistiocytosis: A retrospective safety and activity analysis

Multi-dimensional transcriptomic profiling reveals novel tumor microenvironment landscape and subtype-specific therapeutic Vulnerabilities of MALT lymphomas

Preliminary analysis of a phase 2b, randomized, active-control study of flonoltinib maleate (FM) vs. ruxolitinib in intermediate-2 or high-risk myelofibrosis patients

A multifunctional nanoplatform for ferroptosis inducing/chemo/photothermal therapy enhances therapeutic effect and prevents adverse gastrointestinal reaction of methotrexate

Efficacy and safety of orelabrutinib monotherapy in patients with chronic lymphocytic leukemia: A retrospective real-world study

Teclistamab in a large cohort of ~100 Asian patients with triple-class exposed multiple myeloma: Experience from trials and non-trial settings

Effectiveness and safety of axicabtagene ciloleucel (Axi-cel) in Chinese patients with relapsed/refractory non-Hodgkin lymphoma: Age subgroup analysis of real-world study

Health-related quality of life in Chinese multiple myeloma patients treated with daratumumab-based regimens in real world: Exploratory analysis of the MMY4032

Research on allogeneic CAR-T.BiTE cells targeting CLL-1/siglec-6 for the treatment of Acute Myeloid Leukemia

Effects of golidocitinib and gecacitinib in mouse models of primary and secondary hemophagocytic lymphohistiocytosis

A novel conditioning regimen combining selinexor with melphalan Improves Survival in Patients with multiple myeloma:a prospective study

Results of a registrational Phase 2 study of lisaftoclax monotherapy for treatment of patients (pts) with Relapsed/Refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who had failed Bruton's tyrosine kinase inhibitors (BTKis)

Real world outcomes of zanubrutinib monotherapy for CLL/SLL focusing on treatment discontinuation and BTKi switching: A single center retrospective analysis

High HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory peripheral T-cell lymphoma: A single-agent phase IIa study

Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma in Chinese population: A single-arm, multicenter, phase 2 trial

Early efficacy and safety of luspatercept in myelofibrosis-associated anemia: A clinical study with biomarker exploration

DARS mediated M2 polarization of tumor associated macrophages drives MPN progression

Real-world safety profile of PD-1 inhibitors in Epstein–Barr Virus–Associated lymphoproliferative disorders: A retrospective analysis from west China hospital

S100A12-Orchestrated Macrophage-ER stress crosstalk in MDS: Mechanisms and precision therapeutic targeting

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only